Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
대표청구항▼
1. A compound of Formula (II): or a pharmaceutically acceptable salt, hydrate, or solvate, thereof, wherein:each of X and Y is independently selected from —CH3 and —CD3;at least one of X and Y is —CD3;each of R15, R17, and R18 is independently selected from hydrogen and deuterio; andthe level of deu
1. A compound of Formula (II): or a pharmaceutically acceptable salt, hydrate, or solvate, thereof, wherein:each of X and Y is independently selected from —CH3 and —CD3;at least one of X and Y is —CD3;each of R15, R17, and R18 is independently selected from hydrogen and deuterio; andthe level of deuterium enrichment at each position denoted D is at least 50%. 2. The compound of claim 1, wherein R15 is deuterio and each of R17 and R18 is hydrogen. 3. The compound of claim 1, wherein R17 is deuterio and each of R15 and R18 is hydrogen. 4. The compound of claim 1, wherein R18 is deuterio and each of R15 and R17 is hydrogen. 5. The compound of claim 1, wherein each of R15 and R17 is deuterio, and R18 is hydrogen. 6. The compound of claim 1, wherein each of R15 and R18 is deuterio, and R17 is hydrogen. 7. The compound of claim 1, wherein each of R17 and R18 is deuterio, and R15 is hydrogen. 8. The compound of claim 1, wherein each of R15, R17, and R18 is deuterio. 9. The compound of claim 1, wherein X is —CD3 and Y is —CH3. 10. The compound of claim 1, wherein each of X and Y is —CD3. 11. The compound of claim 1, wherein the level of deuterium enrichment at each position denoted D in moiety X and Y is at least 70%. 12. The compound of claim 1, wherein the level of deuterium enrichment at each position denoted D in moiety X and Y is at least 90%. 13. The compound of claim 1, wherein the level of deuterium enrichment at each position denoted D in moiety X and Y is at least 98%. 14. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable excipient. 15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises an oral formulation. 16. An oral dosage form comprising the pharmaceutical composition of claim 15. 17. An oral dosage form comprising the compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate, thereof. 18. A method of treating a gram negative bacterial infection in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate, thereof. 19. The method of claim 18, wherein the method further comprises administering to the patient a therapeutically effective amount of a β-lactamase inhibitor, a carbapenemase inhibitor, or a combination thereof. 20. The method of claim 18, wherein the method further comprises administering to the patient a therapeutically effective amount of clavulanic acid, sulbactam, avibactam, tazobactam, relebactam, vaborbactam, ETX 2514 ((2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl hydrogen sulfate), RG6068, or a combination of any of the foregoing. 21. The method of claim 18, wherein the method further comprises administering to the patient a therapeutically effective amount of avibactam. 22. The method of claim 18, wherein the method further comprises administering to the patient a therapeutically effective amount of lindamycin, erythromycin, metronidazole, a penicillin, vancomycin, or a combination of any of the foregoing. 23. A method of treating a bacterial infection in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate, thereof, wherein the bacterial infection can be treated by administering tigemonam to a patient. 24. A method of treating a gram negative bacterial infection in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate, thereof, wherein each of X and Y is —CD3, and each of each of R15, R17, and R18 is hydrogen. 25. A method of treating a bacterial infection in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate, thereof, wherein the bacterial infection can be treated by administering tigemonam to a patient, and wherein each of X and Y is —CD3, and each of each of R15, R17, and R18 is hydroqen.
Gordon Eric M. (Pennington NJ) Ondetti Miguel A. (Princeton NJ), Antibacterial O-sulfated b
상세보기
Yuzhakov Vadim Vladimirovich ; Sherman Faiz Feisal ; Owens Grover David ; Gartstein Vladimir, Apparatus and method for using an intracutaneous microneedle array.
Slusarchyk William A. (Belle Mead NJ) Dejneka Tamara (Skillman NJ), Certain carbamate ester derivatives forming salts with pyridinium or picolinium cations which are useful as intermediate.
Oh, Jong Eun; Lee, Keon Hyoung; Park, Tae Gwan; Nam, Yoon Sung, Controlled drug delivery system using the conjugation of drug to biodegradable polyester.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Yatvin Milton B. ; Stowell Michael H. B. ; Gallicchio Vincent S. ; Meredith Michael J., Covalent microparticle-drug conjugates for biological targeting.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Calanchi Massimo,ITX ; Zema Marco,ITX ; Brunetti Gabriele,ITX ; Giorgetti Enzo,ITX, Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Venkateshwaran Srinivasan ; Fikstad David ; Ebert Charles D., Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Saikawa, Akira; Igari, Yasutaka; Hata, Yoshio; Yamamoto, Kazumichi, Sustained release compositions, process for producing the same and utilization thereof.
Bodmer David (Klingnau CHX) Fong Jones W. (Parsippany NJ) Kissel Thomas (Staufen DEX) Maulding Hawkins V. (Mendham NJ) Nagele Oskar (Sissach CHX) Pearson Jane E. (Ogendensburg NJ), Sustained release formulations of water soluble peptides.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Targeted gas and gaseous precursor-filled liposomes.
Friend David R. ; Ng Steve ; Sarabia Rafael E. ; Weber Thomas P. ; Geoffroy Jean-Marie, Taste-masked microcapsule compositions and methods of manufacture.
Norris James ; Clawson Gary ; Westwater Caroline ; Schofield David ; Schmidt Michael ; Hoel Brian ; Dolan Joseph ; Pan Wei-Hua, Tissue-specific and pathogen-specific toxic agents and ribozymes.
Slusarchyk William A. (Belle Mead NJ) Koster William H. (Pennington NJ), [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy].
※ AI-Helper는 부적절한 답변을 할 수 있습니다.